Both Cordlife Hong Kong Limited (Cordlife) and Hong Kong Regen MedTech Limited (HKRM), partners of the Hong Kong Science and Technology Parks Corporation (HKSTP), have announced their collaboration to co-launch a regenerative medical initiative centred on the biology of mesenchymal stem cells (MSCs). Patients with degenerative arthritis have optimistic futures thanks to the quick advancement of regenerative medicine.
Injections of hyaluronic acid or corticosteroids are currently the most used non-surgical treatments for osteoarthritis. There are worries regarding the potential negative effects of corticosteroids, and these treatments might not be appropriate for all patients. Patients endure misery while they wait for full joint replacement surgery in Hong Kong, where there are currently close to 35,000 cases on the waiting list. Artificial joints also have a finite “lifespan” of about 20 years, and the doctor should determine whether such treatment is appropriate for the patient.
For people with osteoarthritis, the quick development of regenerative medicine has exciting promises. At the Hong Kong Science Park, partner companies HKRM and Cordlife held a press conference with the theme “Advancing Stem Cell Therapy: A Journey of Collaboration and Innovation” as part of the HKSTP’s “Medtech Co-Create” project. HKRM and Cordlife announced joint studies on regenerative medicine with the assistance of HKSTP. The partnership intends to promote the growth of regenerative medicine in Hong Kong as well as raise public knowledge of the field. The ultimate objective is to offer patients a minimally intrusive, safe, and effective therapeutic choice.
| Read More news: Click here |
